GRACE

cancergrace.org

 

GRACE
Avatar

2020 ASCO Highlights on RT+ Chemo in LS-SCLC: Is There a Difference in Efficacy & Toxicity Between Lower vs. Higher Dose Twice Daily?

By GRACE FEATURING Jack West, Helena Yu, David Spigel
By GRACE FEATURING Jack West, Helena Yu, David Spigel
0 views
December 10, 2020
Comments 0
Login to view comments. Click here to Login

Featured Video

23:35
University of Colorado Division of Hematology

2024 Updates in PV/ET

Feat. B. McMahon

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison
Lung
04:01
GRACE

Lung Resection in Early Stage NSCLC: An Overview

Feat. C. Jeffrey Yang
05:58
GRACE

Future Goals of mNSCLC Treatment

Feat. P. Iyengar
06:13
GRACE

The NRG-LU Trial: Maintenance Systemic Therapy vs. Local Consolidati…

Feat. P. Iyengar
06:14
GRACE

Using Radiation to Improve Outcomes and QoL in Patients With mNSCLC

Feat. P. Iyengar
02:41
GRACE

Staging Disease: How Oncologists Stage NSCLC

Feat. I. Dagogo-Jack, M. Das, C. Jeffrey Yang
03:19
GRACE

Biomarkers in NSCLC

Feat. I. Dagogo-Jack, M. Das, C. Jeffrey Yang
06:09
GRACE

Perioperative vs. Preoperative Surgery in NSCLC

Feat. I. Dagogo-Jack, M. Das, C. Jeffrey Yang
03:25
GRACE

Antibody Drug Conjugates and How They Are Used in NSCLC

Feat. L. Bazhenova
02:36
GRACE

ADC Treatment in NSCLC

Feat. L. Bazhenova
03:15
GRACE

Bispecific Antibodies in Lung Cancer

Feat. L. Bazhenova
02:52
GRACE

Amivantamab in 1L Advanced NSCLC With EGFR exon 20 Insertion Mutatio…

Feat. L. Bazhenova
05:47
GRACE

Treatment Options for EGFR+ NSCLC

Feat. I. Dagogo-Jack, N. Vokes
03:42
GRACE

Surgical Options for Stage IV NSCLC With Brain Metastases: 60 y/o Wo…

Feat. I. Dagogo-Jack, J. Reuss
06:02
GRACE

Neoadjuvant Chemo +/- Nivo for Patients With Early Stage NSCLC: Case…

Feat. I. Dagogo-Jack, J. Reuss
03:21
GRACE

Treating Stage III NSCLC: Case-Based Panel Discussion

Feat. I. Dagogo-Jack, K. Arbour
03:44
GRACE

How Oncologists Stage Disease - Case-Based Panel Discussion: 50 y/o …

Feat. I. Dagogo-Jack, J. Reuss, N. Vokes, K. Arbour
09:37
GRACE

Is Broad NGS the Standard of Care in Advanced NSCLC?

Feat. I. Dagogo-Jack, M. Marmarelis, A. Sacher, A. Hegde
05:27
GRACE

Neoadjuvant Therapy vs. Adjuvant Therapy in NSCLC: What Is the Futur…

Feat. J. West, E. Rodriguez, R. Shah, N. Duma
05:38
GRACE

Surgical vs. Nonsurgical Treatment in Early NSCLC

Feat. J. West, E. Rodriguez, R. Shah, N. Duma
07:28
CancerGRACE

Early Stage NSCLC: PD-L1 and Durvalumab

Feat. J. West, E. Rodriguez, R. Shah, N. Duma
04:35
GRACE

Testing in Potentially Resectable & Unresectable Locally Advance…

Feat. J. West, E. Rodriguez, R. Shah, N. Duma
22:49
CancerGRACE

The Need for Broad Molecular Testing for Driver Mutations in NSCLC

Feat. J. Gainor
26:08
GRACE

NSCLC Frontline Therapy for Uncommon Mutations: Overview of RET, NTR…

Feat. J. Gainor
06:15
CancerGRACE

Expert Discussion on Targeted Therapy for mNSCLC: Can ALK Inhibitors…

Feat. J. West
18:10
GRACE

A Case of a NSCLC KRAS 71 y/o Female With Underlying Autoimmune Cond…

Feat. S. Liu, J. Brahmer, B. Levy
15:42
CancerGRACE

Expert Analysis of 1L EGFR+ Advanced NSCLC Options: 1st Gen Gefitini…

Feat. J. Weiss
10:33
GRACE

Targeted Therapy for EGFR+ NSCLC: How Do We Think About Acquired Res…

Feat. Z. Piotrowska
18:15
CancerGRACE

Targeted Therapy for EGFR+ NSCLC: What Are the Current Options Upon …

Feat. Z. Piotrowska
05:41
GRACE

ASCO Expert Discussion on Malignant Pleural Mesothelioma: Does Durva…

Feat. J. West, H. Yu, D. Spigel
05:47
GRACE

ASCO Roundtable on 2L Malignant Pleural Mesothelioma: How Encouragin…

Feat. J. West, H. Yu, D. Spigel
10:25
CancerGRACE

IO for Unresectable Stage 3 NSCLC: Does Durvalumab Help Patients? Wh…

Feat. M. Das
08:13
CancerGRACE

2020 ASCO Highlights on RT+ Chemo in LS-SCLC: Is There a Difference …

Feat. J. West, H. Yu, D. Spigel
16:22
GRACE

2020 ASCO ADAURA Trial Update on Adjuvant Osimertinib in EGFR+ NSCLC…

Feat. H. Yu, D. Spigel, J. West
11:28
CancerGRACE

2020 ASCO Update on 1L Advanced NSCLC: Is Nivo + Ipi + Limited Cours…

Feat. H. Yu, D. Spigel, J. West
11:22
CancerGRACE

2020 ASCO Update on Advanced NSCLC: What Is the Role for Nivolumab/I…

Feat. H. Yu, D. Spigel, J. West
09:02
CancerGRACE

2020 ASCO Update on MET/RET+ NSCLC: How Promising Are Capmatinib &am…

Feat. H. Yu, D. Spigel, J. West
08:25
CancerGRACE

2020 ASCO Update on HER2+ NSCLC: Is There a Promising Clinical Activ…

Feat. H. Yu, D. Spigel, J. West
12:16
CancerGRACE

2020 ASCO Update on EGFR+ NSCLC: Does Upfront SBRT to Sites at Diagn…

Feat. H. Yu, D. Spigel, J. West
08:16
CancerGRACE

ASCO 2020 Updates on PD-L1 NSCLC: Is Tiragolumab+Atezo Beneficial fo…

Feat. J. West, H. Yu, D. Spigel
05:32
GRACE

2020 Updates on SCLC: Have We Progressed in the Treatment of Relapse…

Feat. T. Owonikoko
05:16
CancerGRACE

Liquid Biopsy in NSCLC: Does Adding Liquid Biopsy to Tissue Testing …

Feat. C. Aggarwal
06:45
GRACE

SCLC Updates: What Are the Leading Immunotherapy Options?

Feat. S. Liu
05:38
GRACE

Expert Discussion on mNSCLC: What Are the Leading Treatment Options …

Feat. S. Liu
05:45
GRACE

2020 Update on Molecular Abnormalities in NSCLC: How Do MET Exon 14 …

Feat. J. Bauml
05:56
GRACE

The Role of IO for NSCLC Patients With Driver Mutations: What Data D…

Feat. B. Levy
07:43
CancerGRACE

2020 Update on Targeted Therapies in NSCLC PD-L1 Expression: What Ar…

Feat. M. Das
07:55
GRACE

Non-Small Cell Lung Cancer: Is Immunotherapy Safe for Frail Patients…

Feat. M. Gubens
05:13
GRACE

Does Immunotherapy Have Activity in Malignant Pleural Mesothelioma?

Feat. M. Das
06:15
CancerGRACE

Non-Small Cell Lung Cancer: How Does a Positive HER2 Mutation Affect…

Feat. J. West, J. Riess, S. Padda
06:03
GRACE

ALK+ NSCLC With High PD-L1. What Is the First Line Treatment for Pot…

Feat. J. West, J. Riess, S. Padda
06:00
CancerGRACE

What Is the Importance of MET Amplification Level in EGFR+ NSCLC Wit…

Feat. C. McCoach, H. Wakelee, J. West
03:45
GRACE

NSCLC EGFR Mutation Treated With Tagrisso: Progression While on Trea…

Feat. C. McCoach, H. Wakelee, J. West
07:30
CancerGRACE

NSCLC EGFR Mutation and the FLAURA Trial: Is There a Difference in D…

Feat. C. McCoach, H. Wakelee, J. West
08:20
GRACE

EGFR + NSCLC: Is There a Place for Chemo and the Inclusion of Immuno…

Feat. J. West, H. Wakelee, C. McCoach
04:14
CancerGRACE

EGFR Mutation and High and High PD-L1 in NSCLC: What is the Role of …

Feat. C. McCoach, H. Wakelee, J. West
05:18
CancerGRACE

Non-Small Cell Lung Cancer: What Are the Recommended Treatments for …

Feat. C. McCoach, H. Wakelee, J. West
05:04
CancerGRACE

NSCLC With EGFR Mutation: What Are the Treatment Options with Oligop…

Feat. C. McCoach, H. Wakelee, J. West
07:12
CancerGRACE

NSCLC With EGFR Mutation: Is There a Place for Chemotherapy and an E…

Feat. C. McCoach, H. Wakelee, J. West
05:52
CancerGRACE

NSCLC With EGFR Uncommon Exon 20 Mutation: Suggested Treatments, Tar…

Feat. C. McCoach, H. Wakelee, J. West
04:20
GRACE

The Challenges of Potential Pneumonitis Following Durvalumab in Stag…

Feat. M. Gubens, J. West, M. Das
06:03
CancerGRACE

Would IO Be Beneficial for Stage 3 NSCLC Patient with PDL1-0 After S…

Feat. M. Gubens, J. West, M. Das
08:02
CancerGRACE

Best Schedule for Durvalumab for Older Patient in Stage 3 NSCLC Afte…

Feat. J. West, M. Gubens, M. Das
05:12
CancerGRACE

Unresectable NSCLC: What Is TMB and Does it Add Significant Benefit …

Feat. M. Gubens, J. West, M. Das
08:50
GRACE

Does Checkmate 227's Suggestion of an IO Combination of Ipi + N…

Feat. M. Gubens, J. West, M. Das
10:58
CancerGRACE

Should Molecular Tests Be Considered in Stage 3 NSCLC and Would Outc…

Feat. M. Gubens, J. West, M. Das
09:22
CancerGRACE

Case of 60 y/o Woman with ALK Positive Metastatic NSCLC: Approach to…

Feat. S. Padda, J. Riess, J. West
06:14
GRACE

Case of ALK Positive Patient with Asymptomatic Brain Metastases: Is …

Feat. S. Padda, J. Riess, J. West
09:45
GRACE

Treatment for NSCLC Patient Who Developed Resistance to ALK Inhibito…

Feat. S. Padda, J. Riess, J. West
11:11
GRACE

Is the Standard Treatment the Best Approach for Stage 3 Frail Patien…

Feat. M. Gubens, J. West, M. Das
06:43
CancerGRACE

Should We Continue the ALK Inhibitor in NSCLC Patient with Brain Met…

Feat. S. Padda, J. Riess, J. West
10:53
CancerGRACE

Is There a Role for Combination Therapies Like Chemo/Radio and IO fo…

Feat. S. Padda, J. Riess, J. West
09:53
GRACE

Stage 3 NSCLC - Standard Concurrent Chemo + Radiation, Followed by I…

Feat. M. Gubens, J. West, M. Das
11:27
CancerGRACE

Stage 3 NSCLC: Is the Standard Treatment of Chemo and Radiation Foll…

Feat. M. Gubens, J. West, M. Das
11:26
CancerGRACE

Case Based Discussion on Stage 3 NSCLC: Should We Do Molecular Tests…

Feat. M. Gubens, J. West, M. Das
05:24
GRACE

CancerGRACE's ASCO 2019 Update on Lung Cancer: How Promising is…

Feat. J. West, B. Levy, C. Aggarwal
05:32
CancerGRACE

CancerGRACE's ASCO 2019 Update on Lung Cancer: Short Discussion…

Feat. J. West, B. Levy, C. Aggarwal
06:02
CancerGRACE

CancerGRACE's ASCO 2019 Update on Lung Cancer: Circulating Tumo…

Feat. J. West, B. Levy, C. Aggarwal
05:53
CancerGRACE

CancerGRACE's ASCO 2019 Update on Lung Cancer: Retrospective An…

Feat. J. West, B. Levy, C. Aggarwal
03:55
CancerGRACE

CancerGRACE's ASCO 2019 Update on Stage IV NSCLC: New Targets -…

Feat. J. West, B. Levy, C. Aggarwal
06:33
CancerGRACE

CancerGRACE's ASCO 2019 Highlights and New Approaches in Stage …

Feat. J. West, B. Levy, C. Aggarwal
07:14
CancerGRACE

CancerGRACE's ASCO 2019 Highlights and New Approaches in Stage …

Feat. J. West, B. Levy, C. Aggarwal
06:33
CancerGRACE

CancerGRACE's 2019 ASCO Highlights in Advanced NSCLC: What is t…

Feat. J. West, B. Levy, C. Aggarwal
06:38
CancerGRACE

CancerGRACE's 2019 ASCO Highlights on Adjuvant Afatinib in Stag…

Feat. J. West, B. Levy, C. Aggarwal
07:26
CancerGRACE

CancerGRACE's 2019 ASCO Highlights on Stage I NSCLC Adjuvant Ch…

Feat. J. West, B. Levy, C. Aggarwal
21:24
GRACE

Is There a Role for IO in EGFR+ Metastatic Lung Cancer?

Feat. H. Yu
47:56
CancerGRACE

Initial Treatment and Acquired Resistance in Advanced Lung Cancer &a…

Feat. J. Bauml, J. Sabari
21:58
CancerGRACE

Q&A on Targeted Therapies in Advanced Lung Cancer

Feat. J. Bauml
19:19
GRACE

Introduction to Next Generation Sequencing in Metastatic Lung Cancer…

Feat. J. Bauml
23:26
CancerGRACE

EGFR Initial Treatment and Acquired Resistance in Advanced NSCLC

Feat. H. Yu
09:30
GRACE

Q&A on EGFR Initial Treatment and Acquired Resistance in Advance…

Feat. H. Yu
07:53
CancerGRACE

Optimal First Line Treatment of EGFR+ Advanced NSCLC: First and Seco…

Feat. J. West
18:32
CancerGRACE

Optimal First Line Treatment of EGFR+ Advanced NSCLC: Osimertinib vs…

Feat. J. West
17:04
CancerGRACE

Optimal First Line Treatment of EGFR+ Advanced NSCLC: Dacomitinib, E…

Feat. J. West
17:10
CancerGRACE

Targeted Therapies in Advanced Lung Cancer: What is the Role of Rebi…

Feat. H. Borghaei
26:54
CancerGRACE

Discussion/Q&A on Targeted Therapies in Advanced Lung Cancer

Feat. H. Borghaei
15:23
GRACE

Targeted Therapies in Metastatic NSCLC: Liquid Biopsies as a New Opt…

Feat. C. Aggarwal
02:13
CancerGRACE

Immunotherapy in Stage lll NSCLC - The Pacific Trial and Imfinzi

Feat. K. Kelly
01:54
CancerGRACE

Tumor Mutation Burden in Patients with Non-Squamous NSCLC: Current S…

Feat. S. Patel
02:41
CancerGRACE

Evolving Standards for Molecular Testing in Advanced NSCLC

Feat. S. Patel
02:05
CancerGRACE

Combinations of Immunotherapy Agents in Advanced NSCLC: Current Stat…

Feat. S. Patel
02:17
GRACE

The Basics of Managing Immune-Mediated Side Effects in NSCLC

Feat. S. Patel
03:50
CancerGRACE

What Should Patients With Rapid Progression in Advanced NSCLC Throug…

Feat. J. West
04:46
GRACE

"Consolidation" Radiation After a Good Response to First L…

Feat. J. West
06:57
CancerGRACE

Chemotherapy and Immunotherapy Combinations in Advanced Non-Squamous…

Feat. J. West
05:39
CancerGRACE

Chemo Immuno Therapy Combinations in Advanced Squamous NSCLC

Feat. J. West
07:13
CancerGRACE

Does Immunotherapy Work in Patients with Driver Mutations Like EGFR …

Feat. J. West
04:09
CancerGRACE

EGFR TKI Gilotrif(Afatinib) in Metastatic Squamous NSCLC

Feat. V. Velcheti
04:24
CancerGRACE

Lung Cancer Immunotherapy- Is There Anything Better than PDL1

Feat. V. Velcheti
03:20
GRACE

MET as a Target in Advanced NSCLC

Feat. V. Velcheti
04:33
CancerGRACE

The Changing Landscape of 1L Treatment of ALK-Positive Advanced NSCL…

Feat. A. Shaw
06:02
GRACE

Patterns of Resistance in ALK Positive NSCLC

Feat. A. Shaw
05:04
GRACE

Controlling Brain Metastases in Patients with Molecular Driven Advan…

Feat. A. Shaw
02:14
CancerGRACE

Immunotherapy for Previously Treated Patients with NSCLC

Feat. K. Reckamp
04:50
CancerGRACE

New Options in Acquired Resistance for ALK+ Metastatic Non-small Cel…

Feat. N. Pennell
03:45
CancerGRACE

The Role for Immunotherapy in Patients with a Driver Mutation Lung C…

Feat. N. Pennell
03:35
CancerGRACE

Liquid Biopsies for Broad Genomic Testing in Lung Cancer

Feat. N. Pennell
03:53
CancerGRACE

Liquid Biopsies for EGFR T790M Advanced NSCLC

Feat. N. Pennell
02:45
CancerGRACE

The Role of Angiogenesis in Previously Treated NSCLC

Feat. K. Reckamp
09:07
CancerGRACE

Advanced Non Squamous NSCLC, High PD-L1, No Mutation - Optimal 1st L…

Feat. J. West, Z. Piotrowska, T. Owonikoko
12:59
CancerGRACE

Advanced Non Squamous NSCLC, Low PD-L1, No Mutation - Best Systemic …

Feat. J. West, Z. Piotrowska, T. Owonikoko
11:09
CancerGRACE

Case Based Panel Discussion - Fit Patient Adv Squamous NSCLC Low Tum…

Feat. J. West, Z. Piotrowska, T. Owonikoko
08:18
GRACE

Lung Cancer Case Based Panel Discussion - EGFR and High PDL-1, Choos…

Feat. J. West, Z. Piotrowska, T. Owonikoko
09:21
CancerGRACE

Case Based Panel Discussions - Metastatic Squamous NSCLC Low Tumor P…

Feat. J. West, Z. Piotrowska, T. Owonikoko
08:17
CancerGRACE

Rapid Progression Lung Adenocarcinoma High PD-L1 - How Do You Treat?…

Feat. J. West, Z. Piotrowska, T. Owonikoko
11:15
GRACE

ASCO 2018 - Keynote 042 - Keytruda as a Single Agent Compared to Dou…

Feat. K. Kelly, J. West, S. Patel
12:26
CancerGRACE

ASCO 2018 - Potential Showdown of Two Positive Trials? Keynote 407 a…

Feat. K. Kelly, J. West, S. Patel
11:29
CancerGRACE

ASCO 2018 Keynote189 - Cisplatin or Carboplatin with Alimta & Ke…

Feat. K. Kelly, J. West, S. Patel
09:40
CancerGRACE

ASCO 2018 - Checkmate 227 - Combinations of Nivolumab and Ipilimumab…

Feat. K. Kelly, J. West, S. Patel
07:35
CancerGRACE

ASCO 2018 - Will Taking Mod to High Dose Steroids Affect Lung Cancer…

Feat. K. Kelly, J. West, S. Patel
09:11
CancerGRACE

ASCO 2018 - Tarceva or Tarceva with Avastin as 1st Line for EGFR Pos…

Feat. K. Kelly, J. West, S. Patel
06:27
CancerGRACE

ASCO 2018 - Tarceva Combined with Carboplatin & Alimta - Given U…

Feat. K. Kelly, J. West, S. Patel
02:52
CancerGRACE

ASCO 2018 - Combining Metformin with Standard EGFR Therapy - Is the …

Feat. K. Kelly, J. West, S. Patel
03:34
GRACE

ASCO 2018 - Keynote 158 - Keytruda in Previously Treated, Now Relaps…

Feat. K. Kelly, J. West, S. Patel
04:26
GRACE

ASCO 2018 - Dream Study - Chemo with Imfinzi (durvalumab) for Mesoth…

Feat. K. Kelly, J. West, S. Patel
25:01
CancerGRACE

OncTalk 2018 - Newer Technologies in Radiation - Local Therapies for…

Feat. V. Mehta
21:07
CancerGRACE

OncTalk 2018 - Novel Indications for Local Therapy in Adv NSCLC - Lo…

Feat. P. Iyengar
19:01
GRACE

NSCLC - Local Therapies for Metastatic LC

Feat. E. Vallieres
27:13
CancerGRACE

OncTalk 2018 - Systemic Therapies for Advanced NSCLC - Local Therapi…

Feat. J. West
45:31
CancerGRACE

OncTalk 2018 - Panel Discussion and Q&A - Local Therapies for Me…

Feat. E. Vallieres, J. West, V. Mehta, P. Iyengar